Jonathan W Engle
Overview
Explore the profile of Jonathan W Engle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
2643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Whetter J, Smilowicz D, Becker K, Aluicio-Sarduy E, Kelderman C, Koller A, et al.
J Am Chem Soc
. 2024 Nov;
146(48):33121-33129.
PMID: 39570707
Radioisotopes of fluorine (F), scandium (Sc, Sc), lutetium (Lu), and yttrium (Y, Y) have decay properties ideally suited for targeted nuclear imaging and therapy with small biologics, such as peptides...
12.
Li X, Song W, Engle J, Mixdorf J, Barnhart T, Sun Y, et al.
Mol Pharm
. 2024 Nov;
21(12):6411-6422.
PMID: 39533706
CD93 is overexpressed in multiple solid tumor types, serving as a novel target for antiangiogenic therapy. The goal of this study was to develop a Cu-based positron emission tomography (PET)...
13.
Olson A, Verich F, Ellison P, Aluicio-Sarduy E, Nickles R, Mixdorf J, et al.
EJNMMI Radiopharm Chem
. 2024 Oct;
9(1):72.
PMID: 39438347
Background: Radiopharmaceutical therapy (RPT) uses radionuclides that decay via one of three therapeutically relevant decay modes (alpha, beta, and internal conversion (IC) / Auger electron (AE) emission) to deliver short...
14.
Kelderman C, Glaser O, Whetter J, Aluicio-Sarduy E, Mixdorf J, Sanders K, et al.
Chem Sci
. 2024 Oct;
PMID: 39397825
The widely established PET isotope F does not have a therapeutic partner. We have recently established that the Sc-F bond can be formed under aqueous, high yielding conditions, paving the...
15.
Hierlmeier I, Marino N, Schreck M, Schneider L, Maus S, Barrett K, et al.
Inorg Chem
. 2024 Oct;
63(41):19468-19481.
PMID: 39352711
In this work, we describe the complex formation and radiochemistry of the cyclen-based chelator DOTI-Me bearing four methylimidazole arms. Radiolabeling properties were evaluated for Mn, Cu, Ga, In, Tb, and...
16.
Lin W, Smilowicz D, Joaqui-Joaqui M, Bera A, Zhong Z, Aluicio-Sarduy E, et al.
Angew Chem Int Ed Engl
. 2024 Sep;
63(50):e202412357.
PMID: 39312186
The elementally matched Co (t=17.53 h, I=77 %)/Co (t=9.10 h, internal conversion=100 %) radioisotope pair is of interest for development of paired diagnostic/therapeutic radiopharmaceuticals. Due to the accessibility of the...
17.
Rosenkrans Z, Thickens A, Kink J, Aluicio-Sarduy E, Engle J, Hematti P, et al.
Mol Pharm
. 2024 Aug;
21(9):4324-4335.
PMID: 39164886
Positron emission tomography (PET) is a powerful tool for investigating the in vivo behavior of drug delivery systems. We aimed to assess the biodistribution of extracellular vesicles (EVs), nanosized vesicles...
18.
Kerr C, Sheehan-Klenk J, Grudzinski J, Adam D, Nguyen T, Ferreira C, et al.
bioRxiv
. 2024 Jul;
PMID: 39071353
Teaser: This study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
19.
Fonseca Cabrera G, Ma X, Lin W, Zhang T, Zhao W, Pan L, et al.
J Nucl Med
. 2024 Jun;
65(8):1250-1256.
PMID: 38871388
The development of theranostic radiotracers relies on their binding to specific molecular markers of a particular disease and the use of corresponding radiopharmaceutical pairs thereafter. This study reports the use...
20.
Rosenkrans Z, Erbe A, Clemons N, Feils A, Medina-Guevara Y, Jeffery J, et al.
bioRxiv
. 2024 Jun;
PMID: 38853889
Objectives: Disialoganglioside 2 (GD2), overexpressed by cancers such as melanoma and neuroblastoma, is a tumor antigen for targeted therapy. The delivery of conventional IgG antibody technologies targeting GD2 is limited...